Widely read:
Adobe Stock
Dr. Reddy's Laboratories is set to announce its Q4 FY25 earnings on May 9, 2025. Market analysts expect a solid performance backed by strategic acquisitions, strong execution across key markets, and contributions from new business verticals.
Revenue Outlook
The company's consolidated revenue is projected to rise approximately 15.5 per cent year-on-year (YoY) to around ₹7,020 crore. This strong growth is primarily driven by the integration of the Haleon over-the-counter (OTC) business and steady traction from the generic version of Revlimid (gRevlimid), which alone is expected to contribute about $160 million in quarterly sales.
Profit Expectations
Net profit is estimated to increase by 14.95 per cent YoY, reaching around ₹1,022 crore. This growth reflects effective cost management, operational efficiencies, and the company's ability to monetise its strategic assets.
Margin Considerations
EBITDA margins are likely to expand to 26.1 per cent, a YoY increase of 24.35 per cent. However, analysts caution that price erosion in the U.S. generics market and the waning exclusivity of gRevlimid could begin to weigh on profitability in the coming quarters. These developments could act as a headwind despite the topline growth.
Strategic Developments
Dr. Reddy's domestic business continues to gain momentum, aided by recent strategic partnerships. The licensing deal with Sanofi for vaccine distribution and the joint venture with Nestlé to expand in the nutraceutical segment are expected to enhance the company's long-term market presence and broaden its product portfolio.
Stock Performance and Valuation
As of May 7, 2025, Dr. Reddy's stock trades at ₹1,160.70, commanding a market capitalisation of ₹96,801 crore and a price-to-earnings (P/E) ratio of 18.02. This valuation appears modest when compared to industry peers, suggesting potential upside for long-term investors.
Value Research Stock Rating
Dr. Reddy's Laboratories holds a 4-star rating on Value Research, with component-wise scores as follows:
- Quality Score: 9/10
- Growth Score: 5/10
- Valuation Score: 6/10
- Momentum Score: 5/10
These ratings underscore the company's strong quality fundamentals while indicating a balanced outlook on growth and valuation.
Investment Consideration
Investors are advised to closely track the Q4 results for insights into the company's margin management strategies and integration progress with newly acquired businesses. Despite short-term margin challenges, Dr. Reddy's long-term outlook remains favourable, supported by robust fundamentals and well-placed strategic bets.
For detailed financial information, visit our stock page- Dr. Reddy's Laboratories
Discover stock recommendations and insights with Value Research Stock Advisor. Learn more here.
Disclaimer: This article has been written with the assistance of Artificial Intelligence. While our digital writer has been trained to follow our editorial style, we recommend applying a critical eye while reading. Enjoy the story — and keep smiling with understanding!
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
